Biocartis has announced Herman Verrelst as its new Chief Executive Officer (CEO), effective as of August 2017.
Herman is a seasoned executive and serial entrepreneur with a proven international commercial track-record in molecular diagnostics. Herman currently holds the position of Vice President and General Manager of the Genomics and Clinical Applications Division of Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets with revenues of USD 4.2 billion in 2016. In this role, Herman has been instrumental in expanding Agilent's product portfolio through product innovations and the addition of new technologies. These were primarily in the area of precision genomics for oncology, the gateway to precision medicine, which is an excellent background to assist Biocartis in accelerating its worldwide commercial expansion and test menu development.
Herman joined Agilent in May 2015 as General Manager of the Clinical Applications Division following Agilent's acquisition of Cartagenia, of which Herman was CEO and founder. Cartagenia was a spin-off of Katholieke Universiteit Leuven (Belgium) and was focused on software solutions for clinical genetics and molecular oncology. Prior to that, Herman was CEO of Medicim, which was acquired by the Swiss-based Nobel Biocare AG in 2007, as well as founder and CEO of DATA4s, which was acquired by Norkom Technologies Ltd. in 2004. Herman holds a Master's degree in Electrical Engineering (Katholieke Universiteit Leuven, Belgium).
Rudi Mariën, Chairman of Biocartis, commented: "It is with great excitement that we today announce that Herman will be appointed as our new CEO. Herman has demonstrated true leadership in his previous positions where he realized impressive commercial and shareholder successes. I am confident that under the leadership of Herman, Biocartis will excel in its next phase of growth. We congratulate Herman and wish him all the best in his new role."
The brand new CEO added: "I am passionate by growth stories that are driven by true innovation and as such very pleased to be given the opportunity to join Biocartis. I look forward to work with the team and with Rudi Pauwels, whose passion and vision I share, to continue to disrupt the molecular diagnostics market with solutions that bring precision medicine into practice. The Idylla(TM) platform is an extremely elegant and best-in-class platform to achieve this goal."
Rudi Pauwels, founder of Biocartis, and Hilde Windels, interim CEO, commented: "We are convinced that Herman's commercial track-record, industry experience and personality are a perfect fit for this leadership role within Biocartis. We look forward to work with Herman and to further execute our plans, making sure that Biocartis can impact on a global scale the way molecular diagnostics is performed.